with Prof. Dr. Michael Böhm and Prof. Dr. Holger Thiele
This Medudy course is a video podcast for physicians on the clinically relevant updates to the 2026 ESC Guidelines on Heart Failure. Prof. Dr. Michael Böhm and Prof. Dr. Holger Thiele discuss the new classification of heart failure, the staging system from A to D, and the revised evidence grading system. A key focus is on the interplay between basic drug therapy, additional medication options, and guideline-based interventional procedures. Other topics include the early treatment of decompensated heart failure, the objective assessment of successful recompensation, and the rapid initiation of therapies that improve prognosis. In addition, the experts assess the role of SGLT2 inhibitors, finerenone, and incretin-based therapies in different heart failure phenotypes and demonstrate how the recommendations can be implemented in clinical settings and practice.
Note: All “speakers” appearing in Medudy videos are AI-based avatars used to enhance the educational value of the videos. The individuals on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and has been created and reviewed by the Medudy team of doctors.
At the end of this training you will know:
- The new classification of heart failure, including EF-based treatment recommendations and staging from A to D.
- the differences between basic drug therapy, additional drug options, and guideline-based interventional procedures.
- Guideline-based initial treatment of decompensated heart failure, as well as appropriate parameters for assessing urine output and recovery.
- the importance of early combination therapy with SGLT2 inhibitors and finerenone across the range of ejection fractions.
- the recommendations regarding incretin-based therapies for obesity and heart failure, as well as the current limitations of the evidence regarding reduced ejection fraction.
- Practical strategies for the rapid initiation, titration, and outpatient continuation of therapies that improve prognosis.
